What does Hexarelin do? Benefits and evidence
A peptide that releases growth hormone; repeated use can weaken the response.
Also called: Examorelin, HEX, EP-23905, MF-6003.
Growth hormone secretagogues (ghrelin receptor) · Ghrelin receptor agonist and growth hormone secretagogue.
Hexarelin releases growth hormone and can raise prolactin and cortisol. Small studies tested injections, oral doses and nasal use. Repeated dosing can weaken the GH response. A 16-week study found no significant body-composition benefit. Acute heart effects do not establish treatment benefit or safety for chronic use.
- In small studies, it raised growth hormone, but the effect weakened with repeated use. (Studied in a trial)
- Small short-term studies found brief changes in heart pumping; lasting heart benefits were not shown. (Studied in a trial)
- In a very small study of children, growth speed stayed above their starting level as the hormone effect faded. (Studied in a trial)
Uses in the sources
- Studied to trigger GH release and explore GH-deficiency testing; this is not an approved treatment schedule. (Studied in a trial) (source)
- Small acute studies examined heart pumping function; lasting heart-disease benefits were not established. (Studied in a trial) (source)
- A 16-week SC study found no significant change in lean mass, body fat or bone density. (Studied in a trial) (source)
- A seven-person nighttime study reduced deep sleep despite raising GH. (Studied in a trial) (source)
Related to Hexarelin
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- MK-677 (ibutamoren): This experimental oral drug raises growth hormone and IGF-1; risks include high blood sugar and swelling.
- GHRP-2: A peptide that releases growth hormone and can increase hunger.
- GHRP-6: A peptide studied in growth hormone tests and an experimental stroke combination.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- GENOTROPIN® (somatropin) for injection, for subcutaneous use, FDA · 2025
- 注射用GHRP科研100, PMDA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline., Molitch ME et al. · The Journal of clinical endocrinology and metabolism · 2011
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.